Risco cardiovascular e da síndrome metabólica entre homens com e sem disfunção erétil

estudo caso controle

Autores

  • João Paulo Zambon Hospital Israelita Albert Einstein
  • Rafaela Rosalba de Mendonça Hospital Israelita Albert Einstein
  • Marcelo Langer Wroclawski Hospital Israelita Albert Einstein
  • Amir Karam Junior Hospital Israelita Albert Einstein
  • Raul D. Santos Hospital Israelita Albert Einstein
  • José Antonio Maluf de Carvalho Hospital Israelita Albert Einstein
  • Eric Roger Wroclawski Hospital Israelita Albert Einstein

Palavras-chave:

Disfunção erétil, Síndrome X metabólica, Proteína C-reativa, Doenças cardiovasculares, Endotélio, Fatores de risco

Resumo

CONTEXTO E Objetivo: Disfunção erétil está associada a doenças cardiovasculares. O objetivo foi avaliar o risco cardiovascular através dos critérios de Framingham (FRS), da dosagem de proteína C-reativa e da presença de síndrome metabólica em homens com e sem disfunção erétil diagnosticados em um programa de saúde. TIPO DE ESTUDO E LOCAL: Estudo retrospectivo tipo caso-controle foi realizado. Os pacientes foram selecionados de um programa de saúde do Hospital Israelita Albert Einstein, no período de janeiro a dezembro de 2007. MÉTODOS: 222 homens foram retrospectivamente selecionados e divididos em dois grupos: homens com disfunção erétil (n = 111) e homens sem disfunção erétil (n = 111). Os pacientes foram estratificados de acordo com o Índice Internacional de Disfunção Erétil (International Index of Erectile Function, Erectile Function domain, IIEF-EF domain). A proteína C-reativa e o escore de Framingham foram analisados e os dois grupos foram comparados. RESULTADOS: O nível da proteína C foi significativamente maior entre homens com disfunção erétil (P = 0,04). Pacientes com disfunção erétil também tinham um escore de risco de Framingham alto (P = 0,0015). A proteína C e o escore de Framingham não se correlacionaram com o grau de gravidade da disfunção erétil. A presença de síndrome metabólica foi maior nos pacientes com disfunção erétil (P < 0,05). A gravidade da disfunção erétil esteve diretamente associada com a síndrome metabólica. CONCLUSÃO: Homens com disfunção erétil apresentaram maior risco cardiovascular de acordo com os critérios de Framingham e pela mensuração da proteína C-reativa. A disfunção erétil grave em homens parece ter correlação com a síndrome metabólica.

Downloads

Não há dados estatísticos.

Biografia do Autor

João Paulo Zambon, Hospital Israelita Albert Einstein

MD. Urologist in the Health Review Program, Hospital Israelita Albert Einstein, São Paulo; attending urologist in the Micturition Dysfunction Group, Faculdade de Medicina do ABC (FMABC), Santo André, São Paulo, Brazil.

Rafaela Rosalba de Mendonça, Hospital Israelita Albert Einstein

MD. Urology resident at Faculdade de Medicina do ABC (FMABC), Santo André, São Paulo, Brazil.

Marcelo Langer Wroclawski, Hospital Israelita Albert Einstein

MD. Physician in the Renal Transplantation Group, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Amir Karam Junior, Hospital Israelita Albert Einstein

MD. Urologist in the Health Review Program, Hospital Israelita Albert Einstein, São Paulo; Brazilian Institute of Cancer Control, São Paulo, Brazil.

Raul D. Santos, Hospital Israelita Albert Einstein

MD. Coordinator of the Lipid Clinic, Instituto do Coração (INCOR), São Paulo, Brazil.

José Antonio Maluf de Carvalho, Hospital Israelita Albert Einstein

MD. Coordinator of the Preventive Medicine Center, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Eric Roger Wroclawski, Hospital Israelita Albert Einstein

MD, PhD. Chairman of Urology, Faculdade de Medicina do ABC (FMABC), Santo André; Head of the Department of Urology, Brazilian Institute of Cancer Control; and Urologist at Hospital Israelita Albert Einstein, São Paulo, Brazil. (In memoriam)

Referências

Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res. 2004;16(4):350-3.

Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk fac- tors: prospective results from the Massachusetts male aging study. Prev Med. 2000;30(4): 328-38

Muller A, Mulhall JP. Cardiovascular disease, metabolic syndrome and erectile dysfunction. Curr Opin Urol. 2006;16(6):435-43.

Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in Southern Germany. Circulation. 2004;23:1349-53.

Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assess- ment in the primary prevention of cardiovascular disease. Circulation. 2001;103(13): 1813-8.

Wild SH, Byrne CD. The global burden of the metabolic syndrome and its consequences for diabetes and cardiovascular disease. In: Byrne CD, Wild SH, editors. The Metabolic Syndro- me. Chichester: John Wiley & Sons Ltd; 2005. p.1-43.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.

Giugliano D, Giugliano F, Esposito K. Sexual dysfunction and the Mediterranean diet. Public Health Nutrition. 2006;9(8A):1118-20.

Kupelian V, Shabsigh R, Araujo AB, O’Donnell AB, McKinlay JB. Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study. J Urol. 2006;176(1):222-6.

Heidler S, Temml C, Broessner C, et al. Is the metabolic syndrome an independent risk factor for erectile dysfunction? J Urol. 2007;177(2):651-4.

Bal K, Oder M, Sahin AS, et al. Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunc- tion. Urology. 2007;69(2):356-60.

Greenstein A, Chen J, Miller H, et al. Does severity of ischemic coronary disease correlate with erectile dysfunction? Int J Impot Res. 1997;9(3):123-6.

Chiurlia E, D’Amico R, Ratti C, et al. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol. 2005;46(8):1503-6.

Giugliano F, Esposito K, Di Palo C, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest. 2004;27(7):665-9.

Elesber AA, Solomon H, Lennon RJ, et al. Coronary endothelial dysfunction is associated with erectile dysfunction and elevated asymmetric dimethylarginine in patients with early atherosclerosis. Eur Heart J. 2006;27(7):824-31.

Ulzheimer S, Kalender WA. Assessment of calcium scoring performance in cardiac compu- ted tomography. Eur Radiol. 2003;13(3):484-97.

Derby C, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56(2):302-6.

Kratzik CW, Lackner JE, Märk I, et al. How much physical activity is needed to maintain erectile function? Results of the Androx Vienna Municipality Study. Eur Urol. 2009;55(2): 509-16.

Bansal TC, Guay AT, Jacobson J, Woods BO, Nesto RW. Incidence of metabolic syndro- me and insulin resistance in a population with organic erectile dysfunction. J Sex Med. 2005;2(1):96-103.

Downloads

Publicado

2010-05-05

Como Citar

1.
Zambon JP, Mendonça RR de, Wroclawski ML, Karam Junior A, Santos RD, Carvalho JAM de, Wroclawski ER. Risco cardiovascular e da síndrome metabólica entre homens com e sem disfunção erétil: estudo caso controle. Sao Paulo Med J [Internet]. 5º de maio de 2010 [citado 19º de março de 2025];128(3):137-40. Disponível em: https://periodicosapm.emnuvens.com.br/spmj/article/view/1791

Edição

Seção

Artigo Original